Idarucizumab

Pharmacokinetics

Pharmacokinetic and Toxicokinetic Profile

• Distribution: Volume of distribution limited to the intravascular and nearby extravascular space (0.12 L/kg).
• Metabolism: Normal systemic proteolysis to small peptides and free amino acids.
• Excretion: Rapid renal clearance; Inactive idarucizumab-dabigatran complexes are filtered in the glomerulus and partially reabsorbed in the cells of the proximal convoluted tubule.
• Elimination half-life: Biphasic; with a rapid initial half-life of 45 minutes and a terminal half-life of 10.3 hours.

Indicators and dose

Specific Clinical Indications

• Patients chronically treated with dabigatran who experience life-threatening or uncontrolled acute bleeding (e.g., intracranial hemorrhage, massive gastrointestinal bleeding with hemodynamic instability).
• Need to perform emergency surgical interventions or urgent invasive procedures within a period of less than 8 hours, where it is not possible to wait for the physiological clearance of the drug.

Dosage Scheme and Infusion Protocols

Emergency Management Protocol

The established standard dose is 5 g of idarucizumab intravenously, which is supplied in two consecutive vials of 2.5 g/50 mL each.

1. Administer the first 2.5 g vial as a rapid direct IV infusion over 5-10 minutes, or as a slow bolus injection.
2. Administer the second 2.5 g vial immediately after completing the first.
3. Monitoring: Determine plasma thrombin time or ecarin clotting time before and after administration to confirm reversal of the anticoagulant effect.

Security

Contraindications and Precautions

• There are no absolute contraindications in contexts of potentially lethal hemorrhage.
• Thrombotic Risk: The complete and sudden reversal of anticoagulation restores the patient's baseline prothrombotic state for which dabigatran was required (e.g., atrial fibrillation). Anticoagulant therapy should be reinstituted as soon as clinically safe.